• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于风险概况的多变量纵向生物标志物测量及竞争事件监测间隔在稳定型心力衰竭中的应用

Risk-Profile Based Monitoring Intervals for Multivariate Longitudinal Biomarker Measurements and Competing Events With Applications in Stable Heart Failure.

作者信息

Petersen Teun B, Boersma Eric, Kardys Isabella, Rizopoulos Dimitris

机构信息

Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.

出版信息

Stat Med. 2025 May;44(10-12):e70088. doi: 10.1002/sim.70088.

DOI:10.1002/sim.70088
PMID:40377237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12083058/
Abstract

Patient monitoring is routinely used to detect disease aggravation in many chronic conditions. We propose an adaptive scheduling strategy based on dynamic individual risk predictions that can improve the efficiency of monitoring programs that incorporate multiple longitudinal measurements and competing events. It is motivated by stable chronic heart failure (CHF) patients who are periodically seen to assess the risk of disease aggravation based on multiple patient characteristics and circulating marker protein levels such as NT-proBNP and troponin. We assess the performance of the adaptive strategy versus fixed schedule alternatives using a simulation study based on the Bio-SHiFT study, a cohort of stable CHF patients.

摘要

在许多慢性病中,患者监测通常用于检测疾病恶化情况。我们提出了一种基于动态个体风险预测的自适应调度策略,该策略可以提高包含多个纵向测量和竞争事件的监测计划的效率。其灵感来自于稳定的慢性心力衰竭(CHF)患者,他们会定期接受检查,以便根据多种患者特征以及循环标记蛋白水平(如N末端脑钠肽原和肌钙蛋白)来评估疾病恶化风险。我们使用基于Bio-SHiFT研究(一组稳定的CHF患者队列)的模拟研究,评估了自适应策略与固定调度方案相比的性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/9ec2d4184270/SIM-44-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/5fd0cbdd5087/SIM-44-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/41542289cfe0/SIM-44-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/9ec2d4184270/SIM-44-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/5fd0cbdd5087/SIM-44-0-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/41542289cfe0/SIM-44-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/feca/12083058/9ec2d4184270/SIM-44-0-g001.jpg

相似文献

1
Risk-Profile Based Monitoring Intervals for Multivariate Longitudinal Biomarker Measurements and Competing Events With Applications in Stable Heart Failure.基于风险概况的多变量纵向生物标志物测量及竞争事件监测间隔在稳定型心力衰竭中的应用
Stat Med. 2025 May;44(10-12):e70088. doi: 10.1002/sim.70088.
2
Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure.心力衰竭患者利用利钠肽的血浆浓度的连续测量进行动态危险分层。
Int J Cardiol. 2018 Oct 15;269:196-200. doi: 10.1016/j.ijcard.2018.06.070. Epub 2018 Jun 25.
3
The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure.稳定型心力衰竭患者 N 端脑利钠肽前体的最小信息量监测间隔。
BMC Cardiovasc Disord. 2020 Jun 1;20(1):262. doi: 10.1186/s12872-020-01537-7.
4
Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.糖类抗原125与N末端脑钠肽前体水平:用于心力衰竭预后评估的比较
Tex Heart Inst J. 2012;39(1):30-5.
5
Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study).慢性心力衰竭患者的动态个体化风险预测:92 种生物标志物的纵向临床研究(Bio-SHiFT 研究)。
Sci Rep. 2022 Feb 18;12(1):2795. doi: 10.1038/s41598-022-06698-3.
6
N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.N 端脑利钠肽前体指导的慢性心力衰竭治疗可降低再住院率——TIME-CHF 研究结果。
J Card Fail. 2017 May;23(5):382-389. doi: 10.1016/j.cardfail.2017.02.001. Epub 2017 Feb 13.
7
Longitudinal profile of NT-proBNP levels in ischemic heart failure patients undergoing surgical ventricular reconstruction: The Biomarker Plus study.缺血性心力衰竭患者行心室重建术后 NT-proBNP 水平的纵向分析:Biomarker Plus 研究。
Int J Cardiol. 2018 Jun 1;260:24-30. doi: 10.1016/j.ijcard.2018.02.084. Epub 2018 Feb 26.
8
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure.高敏肌钙蛋白 T、NT-proBNP 和肾小球滤过率:慢性心力衰竭风险分层的多标志物策略。
Int J Cardiol. 2019 Feb 15;277:166-172. doi: 10.1016/j.ijcard.2018.10.079. Epub 2018 Oct 26.
9
Multimarker approach to risk stratification among patients with advanced chronic heart failure.晚期慢性心力衰竭患者风险分层的多标志物方法
Clin Cardiol. 2007 Aug;30(8):397-402. doi: 10.1002/clc.20171.
10
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.联合使用高敏心肌肌钙蛋白 T 和 N 末端脑利钠肽前体可改善慢性心力衰竭患者的预后,优于传统的死亡风险因素。
Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

本文引用的文献

1
HFrEF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms.基于 4210 次重复测量的循环蛋白的 HFrEF 亚型由不同的生物学机制驱动。
EBioMedicine. 2023 Jul;93:104655. doi: 10.1016/j.ebiom.2023.104655. Epub 2023 Jun 14.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3
Personalized screening intervals for kidney function in patients with chronic heart failure: a modeling study.
慢性心力衰竭患者肾功能的个体化筛查间隔:一项建模研究。
J Nephrol. 2021 Oct;34(5):1421-1427. doi: 10.1007/s40620-021-01014-0. Epub 2021 Mar 18.
4
Personalized screening intervals for measurement of N-terminal pro-B-type natriuretic peptide improve efficiency of prognostication in patients with chronic heart failure.用于测量N末端B型利钠肽原的个性化筛查间隔可提高慢性心力衰竭患者的预后预测效率。
Eur J Prev Cardiol. 2021 Aug 9;28(9):e11-e14. doi: 10.1177/2047487320922639.
5
The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure.稳定型心力衰竭患者 N 端脑利钠肽前体的最小信息量监测间隔。
BMC Cardiovasc Disord. 2020 Jun 1;20(1):262. doi: 10.1186/s12872-020-01537-7.
6
Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study.迈向慢性心力衰竭患者的个性化风险评估:Bio-SHiFT研究中NT-proBNP、肌钙蛋白T和CRP的详细时间模式
Am Heart J. 2018 Feb;196:36-48. doi: 10.1016/j.ahj.2017.10.008. Epub 2017 Oct 23.
7
Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests.用于评估预测模型、分子标志物和诊断测试的净效益方法。
BMJ. 2016 Jan 25;352:i6. doi: 10.1136/bmj.i6.
8
Personalized screening intervals for biomarkers using joint models for longitudinal and survival data.使用纵向和生存数据联合模型确定生物标志物的个性化筛查间隔。
Biostatistics. 2016 Jan;17(1):149-64. doi: 10.1093/biostatistics/kxv031. Epub 2015 Aug 28.
9
Combined dynamic predictions using joint models of two longitudinal outcomes and competing risk data.使用两个纵向结果的联合模型和竞争风险数据进行联合动态预测。
Stat Methods Med Res. 2017 Aug;26(4):1787-1801. doi: 10.1177/0962280215588340. Epub 2015 Jun 9.
10
Quantifying and comparing dynamic predictive accuracy of joint models for longitudinal marker and time-to-event in presence of censoring and competing risks.在存在删失和竞争风险的情况下,对纵向标志物和事件发生时间的联合模型的动态预测准确性进行量化和比较。
Biometrics. 2015 Mar;71(1):102-113. doi: 10.1111/biom.12232. Epub 2014 Oct 13.